Thyroid abnormalities associated with better treatment response in CML-CP patients on TKI therapy

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.